Jefferies on Axsome Therapeutics (AXSM): balipodect development rights acquisition 'adds depth to CNS pipeline'
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $245.00 price target on Axsome Therapeutics (NASDAQ: AXSM)The analyst commented, "For ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
